Trials / Completed
CompletedNCT00323934
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGCD0103 | Oral dosage 2 times weekly. |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-10-01
- Completion
- 2008-10-01
- First posted
- 2006-05-10
- Last updated
- 2015-01-08
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00323934. Inclusion in this directory is not an endorsement.